Zobrazeno 1 - 10 of 35 pro vyhledávání: '"Jason Aldred"'
1
Akademický článek
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Autor: Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung
Publikováno v: Neurology and Therapy, Vol 12, Iss 6, Pp 1937-1958 (2023)
Abstract Introduction Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson’s disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) with a single infus
Externí odkaz: https://doaj.org/article/3c28527413ce4845845ba7b0a3dbeb25
Zobrazit plný text záznamu
2
Akademický článek
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance
Autor: Victor S.C. Fung, Jason Aldred, Martha P. Arroyo, Filip Bergquist, Agnita J.W. Boon, Manon Bouchard, Sarah Bray, Sara Dhanani, Maurizio F. Facheris, Nahome Fisseha, Eric Freire-Alvarez, Robert A. Hauser, Anna Jeong, Jia Jia, Pavnit Kukreja, Michael J. Soileau, Amy M. Spiegel, Saritha Talapala, Arjun Tarakad, Enrique Urrea-Mendoza, Jorge Zamudio, Rajesh Pahwa
Publikováno v: Clinical Parkinsonism & Related Disorders, Vol 10, Iss , Pp 100239- (2024)
Background: As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations by the provider. Continuous 24 h/day subcutaneous infusion
Externí odkaz: https://doaj.org/article/ee4b4d82effb4c59b7e2610de99a7111
Zobrazit plný text záznamu
4
Akademický článek
Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
Autor: Rajesh Pahwa, Jason Aldred, Aristide Merola, Niodita Gupta, Emi Terasawa, Viviana Garcia-Horton, David R. Steffen, Prasanna L. Kandukuri, Yanjun Bao, Omar Ladhani, Connie H. Yan, Vivek Chaudhari, Stuart H. Isaacson
Publikováno v: Clinical Parkinsonism & Related Disorders, Vol 8, Iss , Pp 100181- (2023)
Introduction: Carbidopa/levodopa enteral suspension (CLES) previously demonstrated reduction in total daily OFF from baseline by over 4 hours in advanced Parkinson’s disease patients across 54 weeks. Evidence on CLES’s long-term effectiveness on
Externí odkaz: https://doaj.org/article/ed5b36cf53c5474baa6f55f091839295
Zobrazit plný text záznamu
5
Akademický článek
Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients
Autor: Lucas R. Sass, Mohammadreza Khani, Jacob Romm, Marianne Schmid Daners, Kyle McCain, Tavara Freeman, Gregory T. Carter, Douglas L. Weeks, Brian Petersen, Jason Aldred, Dena Wingett, Bryn A. Martin
Publikováno v: Fluids and Barriers of the CNS, Vol 17, Iss 1, Pp 1-14 (2020)
Abstract Background Developing novel therapeutic agents to treat amyotrophic lateral sclerosis (ALS) has been difficult due to multifactorial pathophysiologic processes at work. Intrathecal drug administration shows promise due to close proximity of
Externí odkaz: https://doaj.org/article/9ffaef86f36b40f69fdb3c8159dc0537
Zobrazit plný text záznamu
10
DUOGLOBE : One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
Autor: Marieta Anca-Herschkovitsch, Weining Z. Robieson, Norbert Kovács, Jason Aldred, David G. Standaert, Lars Bergmann, K. Ray Chaudhuri, Pavnit Kukreja, Francesco E. Pontieri, Mihaela Simu, Esther Cubo, Thomas L. Davis, Robert Iansek, Mustafa S. Siddiqui, Paul Bourgeois
Publikováno v: Movement Disorders Clinical Practice
Background Levodopa‐carbidopa intestinal gel (LCIG) is an established treatment for improving motor and some non‐motor symptoms (NMS) in patients with advanced Parkinson's disease (PD). Prospective long‐term data in routine clinical practice ar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1e8ff42f30783003203c6ac2cc16ab3
https://doi.org/10.1002/mdc3.13239
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje